1st Heidelberg HDAC Inhibitor Workshop

“HDAC Inhibitors for the Treatment of Cancer”

June 9 + June 10 (half day), 2008
German Cancer Research Center, Heidelberg

Key topics:
- Mechanism(s) of action
- Therapeutic efficacy in the clinic
- Rational drug combinations

Program

Monday, June 9

08:30-09:00 Opening remarks: Ralph Lindemann and Olaf Witt
Welcome: Prof. Christof von Kalle, Director National Center for Tumor Diseases Heidelberg

09:00 – 10:30 Mechanism(s) of action I (Chair: Ralph Lindemann)
Wynne Aherne (London, UK) HDAC Inhibitors and the molecular chaperone HSP90 – a therapeutic mechanism of action
Manfred Jung (Freiburg, GER) Synthesis and Biological Activity of Histone deacetylase inhibitors that target tubulin
Saverio Minucci (Milan, IT) Chromatin alterations in leukemogenesis

10:30 – 10:45 Coffee Break

10:45 – 12:15 Mechanism(s) of action II (Chair: Ricky Johnstone)
Lucia Altucci (Naples, IT) HDAC Inhibitors: mechanism(s) of action in leukemia models targeting multiple epigenetic enzymes
Hedwig Deubzer (Heidelberg, GER) Activation of BMP4 signaling via inhibition of HDAC11
Thorsten Heinzel (Jena, GER) Mechanisms of HDAC inhibitor action – targets beyond chromatin
Program contd.

12:20 – 13:20  Lunch

13:20 – 14:50  Mechanism(s) of action III (Chair: Olaf Witt)
Rainer Glauben  Histone deacetylase as targets in models of inflammation-related tumorigenesis
(Berlin, GER)

Ralph Lindemann  In vivo candidate screen for apoptotic genes mediating therapeutic activity of
(Heidelberg, GER)  Vorinostat

Martin Göttlicher  HDAC2 in colorectal cancer
(Munich, GER)

14:50 – 15:05  Coffee break

15:05 – 16:35  Clinical efficacy I (Chair: Robert Brown)
Ulrich Mahlknecht  Role of Valproic acid in the treatment of AML and MDS
(Homburg/Saar, GER)

Pamela Munster  HDAC inhibitor induced modulation of anti-estrogen therapy
(Tampa, Florida, US)

Kevin Kelly  The early clinical development of Vorinostat (SAHA)
(Yale, Connecticut, US)

Refreshing Break

17:30  Invited speakers: Bus transfer for Tour of the Heidelberg Castle and Old Town

20:00  Invited speakers: Informal Dinner in the Old Town Restaurant “Kulturbrauerei” and further discussions

Tuesday, June 10

09:00 – 10:30  Clinical efficacy II (Chair: Jean-Pierre Issa)
Janine Arts  JNJ-26481585: a novel “second-generation” oral pan-Histone Deacetylase
(Beerse, BEL)  inhibitor

Rudolf Stadler  First experiences with Vorinostat in cutaneous T-cell lymphoma
(Minden, GER)

Nicholas LaThangue  Clinical application of HDAC inhibitors: defining biomarkers that predict tumour
(Oxford, UK)  responses

10:30 – 10:45  Coffee Break
Program contd.

10:45-12:15  Rational drug combinations (Chair: Pamela Munster)
Ricky Johnstone  (Melbourne, Australia)  Enhancing the apoptotic and therapeutic anti-cancer effects of histone deacetylase inhibitors  
Robert Brown  (London, UK)  Combination approaches to overcoming acquired drug resistance in ovarian cancer  
Jean-Pierre Issa  (Houston, Texas, US)  Combinations of DNA methylation inhibitors with histone deacetylase inhibitors in leukemias

12:15  Closing remarks  
12:30-13:30  Lunch and farewell

This workshop is kindly supported by

Supported by:

[List of logos and names]

German José Carreras Leukemia-Foundation

LB BW
Stiftungen 
Landesbank Baden-Württemberg

MSD

dkfz. GERMANY RESEARCH CENTER

NCT
NATIONALES ZENTRUM FÜR TUMORENKrankungen HEIDELBERG

[Other logos and names]